CN208770409U - The preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma - Google Patents
The preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma Download PDFInfo
- Publication number
- CN208770409U CN208770409U CN201820414101.7U CN201820414101U CN208770409U CN 208770409 U CN208770409 U CN 208770409U CN 201820414101 U CN201820414101 U CN 201820414101U CN 208770409 U CN208770409 U CN 208770409U
- Authority
- CN
- China
- Prior art keywords
- compound
- stem cell
- syringe
- tee tube
- rich plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The utility model discloses the preparation facilities of a kind of mescenchymal stem cell and the compound of platelet rich plasma, the preparation facilities includes support base, the support base is equipped with tee tube, and the tee tube releases mouth with the first inlet, the second inlet and compound；It is connected with the first syringe at first inlet, which is used to the mixture of mesenchyma stem cell suspension and platelet rich plasma injecting tee tube；It is connected with the second syringe at second inlet, which is used to agonist injecting tee tube.The mixture of mesenchyma stem cell suspension and platelet rich plasma is injected tee tube through the first inlet by the first syringe, agonist is injected tee tube through the second inlet by the second syringe, the two forms gelatinous compound after mixing in tee tube, the compound releases mouth from compound and releases, and whole process is simple and efficient.
Description
Technical field
The utility model belongs to rotator cuff tendon-bone healing technical field, and in particular to a kind of mescenchymal stem cell and rich platelet
The preparation facilities of the compound of blood plasma.
Background technique
Shoulder joint is the maximum joint of physical activity range, while being also most unstable joint, rotator cuff (Rotator
Cuff it) playing an important role in terms of maintaining Glenohumeral joint stability and ginseng to move, it had not only had the characteristics that general tendon forceps, but also
With unique property.Rotator cuff is different from the typical form of tendon forceps, is by from supraspinatus, infraspinous muscle, subscapular muscle and roundlet
The tendon that the tendon of flesh collectively forms-bone structure complex.
Rotator cuff injury is to cause one of shoulder arthralgia, most common disease of dysfunction, accounts for the 30% of shoulder joint illness.
The success or not of rotator cuff prosthesis is heavily dependent on tendon-bone interface biotic elictor between bone road and tendon, and early
The connection of phase tendon-bone interface is most weak link.Firm tendon-bone interface healing is sent out after ligament reconstructive, rotator cuff prosthetic
The prerequisite of its physiological function is waved, but tendon-bone interface healing is difficult, how to promote tendon-bone interface healing to be increasingly becoming close
The hot spot that domestic and foreign scholars pay close attention to over year.
Occur promoting rotator cuff injury using platelet rich plasma (PRP), mescenchymal stem cell (BMSCs) in the prior art
The tendon-bone healing at position, in use, being usually to directly adopt syringe to do the platelet rich plasma of liquid condition, mesenchyma carefully
Cell lysis liquid is injected into tendon-bone interface between the bone road at rotator cuff injury position and tendon.
Utility model content
This application provides the preparation facilities of a kind of mescenchymal stem cell and the compound of platelet rich plasma.
The preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma, including support base, the support base
It is equipped with tee tube, the tee tube releases mouth with the first inlet, the second inlet and compound；First note
Inlet is connected with the first syringe, which is used for the mixing of mesenchyma stem cell suspension and platelet rich plasma
Object injects tee tube；It is connected with the second syringe at second inlet, second syringe is for injecting agonist
Tee tube.
First syringe is by the mixture of mesenchyma stem cell suspension and platelet rich plasma through the first inlet injection three
Agonist is injected tee tube through the second inlet by siphunculus, the second syringe, and the two forms gelatinous after mixing in tee tube
Compound, the compound release mouth from compound and release, and whole process is simple and efficient.
Preferably, the support base be equipped at least two the first U-shaped decks, first deck it is big
The small outer diameter with first syringe is adapted.
Preferably, the support base be equipped at least two the second U-shaped decks, second deck it is big
The small outer diameter with second syringe is adapted.
Preferably, the support base be equipped at least two U-shaped third decks, the third deck it is big
The small outer diameter with the tee tube is adapted.
Preferably, the compound, which releases exit, is equipped with the arc extended segment being wholely set with tee tube, it is described
The center of arc of arc extended segment is located at tee tube towards support base side.Arc extended segment facilitates compound and smoothly releases.
Preferably, the support base is equipped with for driving the first syringe by mesenchyma stem cell suspension and rich blood
The mixture of platelet-poor plasma at the uniform velocity injects the first driving mechanism of tee tube.
Preferably, the support base is equipped with for driving the second syringe that agonist is at the uniform velocity injected tee tube
Second driving mechanism.
First driving mechanism and the second driving mechanism can not only be such that liquid is at the uniform velocity injected, and drive by adjusting first
The fltting speed of motivation structure and the second driving mechanism, moreover it is possible to make mesenchyma stem cell suspension and platelet rich plasma mixture and
Agonist mixes in certain proportion.
Preferably, first driving mechanism includes the first cylinder, set on the piston end surface of first cylinder
There is push plate, the push plate is opposite with the position of plunger of the first syringe.Preferably, the push plate is towards column
The side for filling in side is equipped with cushion.
Preferably, being equipped with guide slide mechanism between first cylinder and support base.Guide slide mechanism is convenient for
Determine the initial position of the first cylinder, before guaranteeing that the first syringe is started to work, push plate is in contact with the plunger of the first syringe,
Ensure that the first driving mechanism effectively drives.
The structure of second driving mechanism is identical as the first driving mechanism.
Compared with prior art, the utility model has the following beneficial effects:
(1) the application utilizes the first syringe by the mixture of mesenchyma stem cell suspension and platelet rich plasma through first
Inlet injects tee tube, agonist is injected tee tube through the second inlet using the second syringe, the two is in tee tube
Gelatinous compound is formed after mixing, which releases mouth from compound and release, and whole process is simple and efficient；
(2) the first driving mechanism and the second driving mechanism, the first driving mechanism and second is arranged in the application on support base
Driving mechanism can not only make liquid at the uniform velocity be injected tee tube, and by adjusting the first driving mechanism and the second driving mechanism
Fltting speed, moreover it is possible to mix the mixture of mesenchyma stem cell suspension and platelet rich plasma and agonist in certain proportion
It closes, it is ensured that the preparation precision of compound.
Detailed description of the invention
Fig. 1 is the structure of the preparation facilities of the compound of a kind of mescenchymal stem cell of the utility model and platelet rich plasma
Schematic diagram；
Fig. 2 is structural schematic diagram of the tee tube under another visual angle in Fig. 1.
Specific embodiment
The technical solution of the utility model is described in further details with reference to the accompanying drawings and detailed description.
Embodiment 1
As shown in Figure 1, the preparation facilities of the compound of a kind of mescenchymal stem cell of the present embodiment and platelet rich plasma, packet
Support base 1 is included, support base 1 is in tabular, convenient for other component is arranged in its top surface.
Support base 1 is equipped with third deck 11, and third deck 11 is U-shaped, and tee tube 2 is fixed in U-shaped opening.Third
The quantity of deck 11 can be specifically arranged according to specific needs, and the present embodiment is provided with two；As long as guaranteeing the U of third deck 11
The size of type opening and the outer diameter of 2 corresponding position of tee tube are adapted, it is ensured that third deck 11 has the realization of tee tube 2
Effect is fixed.
Tee tube 2 can be T-shaped or Y-shaped, is also possible to other forms.The tee tube 2 of the present embodiment is in T
Shape releases mouth 24 with the first inlet 21, the second inlet 22 and compound；Also, in conjunction with Fig. 2 as it can be seen that being released in compound
The arc extended segment 23 for being additionally provided at 24 and being wholely set with tee tube 2 is exported, the center of arc of the arc extended segment 23 is located at three
Siphunculus 2 is towards 1 side of support base；Setting arc extended segment 23 facilitates compound and smoothly releases.
Wherein, the first syringe 3 is connected at the first inlet 21, the first syringe 3 is for hanging mescenchymal stem cell
The mixture of liquid and platelet rich plasma injects tee tube 2.In order to fix the first syringe 3, it is also provided on support base 1 in U
The outer diameter of first deck 12 of type, the size of the first deck 12 and the first syringe 3 is adapted.The quantity of first deck 12 can also
To be specifically arranged.
The second syringe 4 is connected at second inlet 22, the second syringe 4 is used to agonist injecting tee tube 2, is
The second syringe 4 is fixed, U-shaped the second deck 13, the size and the second note of the second deck 13 are also provided on support base 1
The outer diameter of emitter 4 is adapted.The quantity of second deck 13 also can be specifically set.
As shown in Figure 1, for driving the first syringe 3 by mesenchyma stem cell suspension and rich platelet blood on support base 1
The mixture of slurry at the uniform velocity injects the first driving mechanism 5 of tee tube 2, and for drive the second syringe 4 by agonist at the uniform velocity
Inject the second driving mechanism 6 of tee tube 2.First driving mechanism 5 is identical with the structure of the second driving mechanism 6, the present embodiment with
It is specifically described for first driving mechanism 5.
First driving mechanism 5 includes the first cylinder 51, is fixed with push plate 53, push plate on 52 end face of piston of the first cylinder 51
53 is opposite with the position of plunger 31 of the first syringe 3, also, buffering is equipped on side of the push plate 53 towards 31 side of plunger
Pad 54.
In the present embodiment, guide slide mechanism is equipped between the first cylinder 51 and support base 1.The guide slide mechanism includes
The pulley of first cylinder, 51 bottom is set, is then equipped with the directive slide track 14 being slidably matched with pulley on support base 1.The present embodiment
Provided with two directive slide tracks 14, guarantee that it is oriented to correctness.
In use, first drawing the mesenchyma stem cell suspension of predetermined amount and mixing for platelet rich plasma with the first syringe 3
Object is closed, the first syringe 3 is fixed in the first deck 12, is connected to the first syringe 3 at first inlet 21；With second
Syringe 4 draws the agonist of predetermined amount, and the second syringe 4 is fixed in the second deck 13, the second syringe 4 is connected to
At second inlet 22；The air pressure of first cylinder 51 is set, adjusts the position of the first cylinder 51, supports push plate 53 and cushion 54
On the plunger 31 for leaning against the first syringe 3；The second equally setting of driving mechanism 6；Start the first driving mechanism 5 and the second driving machine
Structure 6 makes the first syringe 3 by the mixture of mesenchyma stem cell suspension and platelet rich plasma through the first inlet 21 injection three
Agonist is injected tee tube 2 through the second inlet 22 by siphunculus 2, the second syringe 4, and the two is formed after mixing in tee tube 2
Gelatinous compound, for the compound i.e. from compound releases mouth 24,23 exit of arc extended segment is released, whole process is easy to be fast
It is prompt.
Claims (10)
1. the preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma, which is characterized in that described including support base
Support base be equipped with tee tube, the tee tube releases mouth with the first inlet, the second inlet and compound；It is described
The first inlet at be connected with the first syringe, which is used for mesenchyma stem cell suspension and rich platelet blood
The mixture of slurry injects tee tube；It is connected with the second syringe at second inlet, second syringe will be for that will swash
Tee tube is injected in dynamic agent.
2. the preparation facilities of the compound of mescenchymal stem cell as described in claim 1 and platelet rich plasma, feature exist
In the support base is equipped at least two the first U-shaped decks, the size of first deck and described first
The outer diameter of syringe is adapted.
3. the preparation facilities of the compound of mescenchymal stem cell as described in claim 1 and platelet rich plasma, feature exist
In the support base is equipped at least two the second U-shaped decks, the size of second deck and described second
The outer diameter of syringe is adapted.
4. the preparation facilities of the compound of mescenchymal stem cell as described in claim 1 and platelet rich plasma, feature exist
In the support base is equipped at least two U-shaped third decks, the size of the third deck and the threeway
The outer diameter of pipe is adapted.
5. the preparation of the compound of mescenchymal stem cell and platelet rich plasma as described in any one of claim 1-4 fills
It sets, which is characterized in that the compound releases exit and is equipped with the arc extended segment being wholely set with tee tube, the arc
The center of arc of extended segment is located at tee tube towards support base side.
6. the preparation of the compound of mescenchymal stem cell and platelet rich plasma as described in any one of claim 1-4 fills
It sets, which is characterized in that the support base is equipped with for driving the first syringe by mesenchyma stem cell suspension and Fu Xue little
The mixture of plate blood plasma at the uniform velocity injects the first driving mechanism of tee tube.
7. the preparation of the compound of mescenchymal stem cell and platelet rich plasma as described in any one of claim 1-4 fills
It sets, which is characterized in that the support base is equipped with for driving the second syringe that agonist is at the uniform velocity injected to tee tube
Two driving mechanisms.
8. the preparation facilities of the compound of mescenchymal stem cell as claimed in claim 6 and platelet rich plasma, feature exist
In first driving mechanism includes the first cylinder, and the piston end surface of first cylinder is equipped with push plate, and described pushes away
Plate is opposite with the position of plunger of the first syringe.
9. the preparation facilities of the compound of mescenchymal stem cell as claimed in claim 8 and platelet rich plasma, feature exist
In the side of the push plate towards plunger side is equipped with cushion.
10. the preparation facilities of the compound of mescenchymal stem cell as claimed in claim 8 and platelet rich plasma, feature exist
In equipped with guide slide mechanism between first cylinder and support base.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820414101.7U CN208770409U (en) | 2018-03-26 | 2018-03-26 | The preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820414101.7U CN208770409U (en) | 2018-03-26 | 2018-03-26 | The preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN208770409U true CN208770409U (en) | 2019-04-23 |
Family
ID=66145653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201820414101.7U Expired - Fee Related CN208770409U (en) | 2018-03-26 | 2018-03-26 | The preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN208770409U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585243A (en) * | 2019-08-12 | 2019-12-20 | 丰泽康生物医药（深圳）有限公司 | Pluripotent cell active matter and platelet-rich plasma compound for treating glucocorticoid-dependent dermatitis as well as preparation method and application thereof |
-
2018
- 2018-03-26 CN CN201820414101.7U patent/CN208770409U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110585243A (en) * | 2019-08-12 | 2019-12-20 | 丰泽康生物医药（深圳）有限公司 | Pluripotent cell active matter and platelet-rich plasma compound for treating glucocorticoid-dependent dermatitis as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gundermann et al. | Activation of mTORC1 signaling and protein synthesis in human muscle following blood flow restriction exercise is inhibited by rapamycin | |
| Maffulli et al. | Novel approaches for the management of tendinopathy | |
| Brower | Anabolic steroid abuse and dependence | |
| IL162586A0 (en) | Improvements in and relating to a medicament injection apparatus | |
| CN208770409U (en) | The preparation facilities of the compound of mescenchymal stem cell and platelet rich plasma | |
| Ferris et al. | Efficacy of deslorelin acetate (SucroMate) on induction of ovulation in American Quarter Horse mares | |
| EP2338516A3 (en) | Multiple-variable dose regimen for treating TNF-alpha-related disorders | |
| Dufloth et al. | Modulation of exercise tachycardia by vasopressin in the nucleus tractus solitarii | |
| Roche et al. | Validated Laser Doppler protocol for measurement of mouse bone blood perfusion—Response to age or ovariectomy differs with genetic background | |
| CN208049141U (en) | A kind of division of endocrinology's clinical orientation device | |
| Wanner et al. | Muscarinic receptors within the ventromedial hypothalamic nuclei modulate metabolic rate during physical exercise | |
| CN208823761U (en) | Simple bowel lavage injects pump installation | |
| CN208627042U (en) | A kind of high-precision Sclerosing foam preparation facilities | |
| Abate et al. | The conservative management of osteoarthritis—hyaluronic acid, platelet-rich plasma or the combination | |
| CN205623545U (en) | Treatment of fruit tree rot is with rifle type syringe | |
| CN205367691U (en) | Filling device of oral liquid | |
| CN106618716A (en) | Bone cement injector | |
| Irvine | The nonpregnant mare: A review of some current research and of the last 25 years of endocrinology | |
| CN115955982A (en) | Device and system for delivering therapeutic agents | |
| CN207679806U (en) | A kind of diabetes extremity ulcer autologous platelet rich gel infusion device | |
| CN208943058U (en) | A kind of duplex mixing syringe with buckle structure | |
| CN204841478U (en) | A agitating unit for preparing tea -seed oil ointment | |
| Miller | Intravenous anaesthesia: new drugs, new concepts, and clinical applications | |
| CN204864368U (en) | Anesthesia is with puncture syringe needle | |
| CN204233554U (en) | One boar adhesive fibrin atomized medicine introducing device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190423 Termination date: 20200326 |